Skip to main content

Stryker Value Stock - Dividend - Research Selection


ISIN: US8636671013 , WKN: 864952

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Stryker's Q Guidance System Scores FDA Clearance For Cranial Applications

Stryker Corporation (NYSE: SYK) announced that its Q Guidance System with Cranial Guidance Software received FDA510(k) clearance. The Q Guidance System is an image-based planning and intraoperative guidance system designed to support cranial surgeries. Recently launched in September 2022, the Q Guidance System for spinal applications is currently available on the market. It tracks navigated instruments and displays the position and orientation of the instruments in patient images. Related: Stryk

Stryker’s Q Guidance System for cranial applications receives FDA clearance

KALAMAZOO, Mich., February 17, 2023--Stryker announced that its Q Guidance System with Cranial Guidance Software received 510(k) FDA clearance.

Stryker: Typically Excellent, Typically Expensive

Stryker posted impressive top-line growth in Q4, driven by mid-teens growth in the MedSurg and Neuro operations. Read more to see my thoughts on SYK stock.

Should Investors Buy This Dividend Growth Stock?

Shares of medical devices company Stryker (NYSE: SYK) have fared even better, ripping 8% higher year to date. Let's delve into Stryker's fundamentals and valuation to figure this out. Improving the lives of more than 100 million patients each year in over 75 countries, Stryker has established itself as a dominant medical devices company.

Globus And NuVasive Take Spinal Fusion To A New Level

Globus and NuVasive's merger deal will see Globus acquire its spinal surgery rival for 0.75 shares of GMED per NUVA share. Read what investors need to know.

Compounders And Dividends: February 2023 Watch List Update

Three companies have been removed from my watchlist and added to the active portfolio. I added four new companies to my watchlist. Read more here.

Stryker (SYK) Declares $0.75 Dividend


Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics

Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

3 Medical Products Stocks Navigating Industry Challenges

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.